Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults
NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy
Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia
Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults
Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors(abciximab [ReoPro], eptifibatide [Integrilin], tirofiban [Aggrastat]) for acute coronary
Evidence-based recommendations on Holoclar for treating limbal stem cell deficiency in adults after eye burns
Evidence-based recommendations on paclitaxel (Taxol) for treating ovarian cancer
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
Evidence-based recommendations on methadone and buprenorphine for the management of opioid dependence
Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C
Evidence-based recommendations on laparoscopic surgery for colorectal (bowel) cancer
Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults
Evidence-based recommendations on docetaxel (Taxotere) for the treatment of hormone-refractory metastatic (advanced) prostate cancer
Evidence-based recommendations on capecitabine (Xeloda) and oxaliplatin (Eloxatin) for adjuvant treatment of stage III (Dukes' C) colon (bowel) cancer
Evidence-based recommendations on the use of inhaler systems (devices) for chronic asthma in children under 5
Evidence-based recommendations on the extraction of wisdom teeth
Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours (cancer of stomach/digestive system)
Evidence-based recommendations on evacizumab (Avastin), soradenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for renal cell carcinoma
Evidence-based recommendatrions on alitretinoin (Toctino) for treating severe chronic hand eczema in adults
Evidence-based recommendations on rituximab (MabThera) for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on tenofovir disoproxil (Viread) for the treatment of chronic hepatitis B (HBV)
Evidence-based recommendations on lenalidomide (Revlimid) for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Evidence-based recommendations on rivaroxaban (Xarelto) for the prevention of venous thromboembolism after total hip or knee replacement in adults
Evidence-based recommendations on sunitinib (Sutent) for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Evidence-based recommendations on amantadine (Lysovir, Symmetrel), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza (flu)
Evidence-based recommendations on endovascular stent–grafts for the treatment of abdominal aortic aneurysms
Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors
Evidence-based recommendations on febuxostat (Adenuric) for the management of hyperuricaemia in people with gout
Evidence-based recommendations on infliximab (Remicade) for acute exacerbations of ulcerative colitis in adults
Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Evidence-based recommendations on spinal cord stimulation (SCS) for chronic pain of neuropathic or ischaemic origin in adults
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for the prevention of venous thromboembolism after hip or knee replacement surgery
Evidence-based recommendations on routine antenatal anti-D prophylaxis for women who are rhesus D negative
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for the treatment of age-related macular degeneration (AMD)
Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B
Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B
Evidence-based recommendations on drug-eluting stents for the treatment of coronary artery disease
Evidence-based recommendations on continuous subcutaneous insulin infusion for the treatment of diabetes mellitus
NICE is unable to make a recommendation about the use in the NHS of carmustine implants because no evidence submission was received from the
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating non-small-cell lung cancer (NSCLC)